KemPharm Inc. (KMPH) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of KemPharm Inc. (NASDAQ:KMPH) from a buy rating to a hold rating in a report released on Wednesday.

According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

A number of other research firms have also weighed in on KMPH. Canaccord Genuity restated a buy rating on shares of KemPharm in a report on Wednesday, August 10th. Oppenheimer Holdings Inc. restated a buy rating and set a $11.00 target price on shares of KemPharm in a report on Tuesday, June 14th.

Shares of KemPharm (NASDAQ:KMPH) opened at 3.80 on Wednesday. The company’s market cap is $55.65 million. The company has a 50 day moving average price of $4.56 and a 200 day moving average price of $7.17. KemPharm has a one year low of $3.52 and a one year high of $20.60.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.36. Equities analysts predict that KemPharm will post ($1.78) EPS for the current year.

In other KemPharm news, EVP Daniel L. Cohen acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the executive vice president now owns 1,310 shares in the company, valued at approximately $6,222.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.80% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. raised its stake in shares of KemPharm by 20.4% in the second quarter. Point72 Asset Management L.P. now owns 383,106 shares of the specialty pharmaceutical company’s stock valued at $1,525,000 after buying an additional 65,030 shares in the last quarter. Menta Capital LLC raised its stake in shares of KemPharm by 312.3% in the second quarter. Menta Capital LLC now owns 47,041 shares of the specialty pharmaceutical company’s stock valued at $187,000 after buying an additional 35,631 shares in the last quarter. Spark Investment Management LLC raised its stake in shares of KemPharm by 195.1% in the second quarter. Spark Investment Management LLC now owns 141,109 shares of the specialty pharmaceutical company’s stock valued at $561,000 after buying an additional 93,284 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of KemPharm by 8.6% in the second quarter. BlackRock Fund Advisors now owns 219,172 shares of the specialty pharmaceutical company’s stock valued at $872,000 after buying an additional 17,400 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of KemPharm by 3.4% in the second quarter. Vanguard Group Inc. now owns 318,210 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after buying an additional 10,390 shares in the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

5 Day Chart for NASDAQ:KMPH

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Disney to Build Larger Hong Kong Kingdom
Disney to Build Larger Hong Kong Kingdom
DraftKings and FanDuel Finally Will Merge
DraftKings and FanDuel Finally Will Merge


 
© 2006-2016 Ticker Report. Google+.